China sanctions another pharma excessive pricing scheme

China sanctions another pharma excessive pricing scheme

China’s antitrust watchdog has fined four companies a total of €156.8 million for inflating the price of an antibacterial drug by up to 62 times more than in other countries.

Unlock unlimited access to all Global Competition Review content